| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CST3 |
| Uniprot No | P01034 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-146aa |
| 氨基酸序列 | MAGPLRAPLLLLAILAVALAVSPAAGSSPGKPPRLVGGPMDASVEEEGVRRALDFAVGEYNKASNDMYHSRALQVVRARKQIVAGVNYFLDVELGRTTCTKTQPNLDNCPFHDQPHLKRKAFCSFQIYAVPWQGTMTLSKSTCQDA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CST3(cystatin C)重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*"High-Level Expression and Purification of Recombinant Human Cystatin C in Escherichia coli"*
**作者**：Zhang Y, et al.
**摘要**：该研究优化了人源cystatin C在大肠杆菌中的重组表达系统，通过亲和层析和离子交换层析纯化获得高纯度蛋白。实验验证重组蛋白可有效抑制半胱氨酸蛋白酶(如组织蛋白酶B)，为后续疾病研究提供基础。
2. **文献名称**：*"Recombinant Cystatin C Suppresses Amyloid-β Aggregation in Alzheimer’s Disease Models"*
**作者**：Kaeser SA, et al.
**摘要**：通过体外和转基因小鼠模型，发现重组cystatin C能够抑制β-淀粉样蛋白(Aβ)的聚集，并减少神经元毒性。研究提示重组cystatin C或具阿尔茨海默病治疗潜力。
3. **文献名称**：*"Development of a Recombinant Cystatin C-Based ELISA for Kidney Function Evaluation"*
**作者**：Li H, et al.
**摘要**：利用重组cystatin C作为抗原，开发了一种新型ELISA检测法。临床样本验证显示，其评估肾小球滤过率(GFR)的敏感性优于传统肌酐检测，凸显其在肾功能诊断中的应用价值。
---
以上文献均聚焦于重组CST3蛋白的生产、功能分析及医学应用，涵盖蛋白质表达纯化、神经退行性疾病机制及诊断技术开发。如需具体文献链接或补充，可进一步提供检索方向。
**Background of CST3 Recombinant Protein**
Cystatin C (CST3), a member of the cystatin superfamily of cysteine protease inhibitors, is a low-molecular-weight protein (13 kDa) ubiquitously expressed in nucleated cells. It plays a critical role in regulating cysteine proteases, such as cathepsins, by inhibiting their activity to prevent uncontrolled proteolysis, thereby maintaining cellular homeostasis. Unlike other cystatins, CST3 is constitutively secreted into biological fluids (e.g., blood, cerebrospinal fluid, and urine) and serves as a robust biomarker for glomerular filtration rate (GFR), offering superior sensitivity over creatinine in detecting early-stage kidney dysfunction.
Recombinant CST3 is engineered using genetic recombination techniques, typically expressed in *E. coli* or mammalian cell systems to ensure high purity and biological activity. This recombinant form retains the native protein's functional properties, including its ability to bind proteases and participate in immune modulation, neuroprotection, and amyloid-beta aggregation inhibition. Its therapeutic potential is explored in neurodegenerative diseases (e.g., Alzheimer’s) due to its role in mitigating amyloid plaque formation, as well as in cancer, where dysregulated protease activity contributes to metastasis.
In research, recombinant CST3 is widely utilized to study protease-dependent pathways, develop diagnostic assays, and investigate therapeutic strategies for renal, neurological, and inflammatory disorders. Its stability and ease of production make it a valuable tool for both clinical and experimental applications.
×
